News | January 30, 2009

Invatec, Lumen Biomedical Partner in Worldwide Distribution Agreement for Embolic Protection Devices

January 30, 2009 – Invatec this week announced it entered a worldwide distribution agreement with Lumen Biomedical Inc. to distribute the FiberNet Embolic Protection System (EPS), which received FDA clearance in November and CE Mark for use during carotid and saphenous vein graft procedures.

When the carotid arteries are obstructed, patients are at an increased risk for stroke, the third leading cause of death in the U.S. The FiberNet EPS captures debris released during the stenting procedure and prevents it from traveling to the brain, where it has the potential to cause a stroke.

The FiberNet system features a three-dimensional design composed of a matrix of fibers that entrap smaller particles and better overall capture efficiency compared to the currently available distal protection filters. The low-profile filter is mounted on a guidewire, needing no delivery system to cross the lesion. The FiberNet EPS will treat vessels ranging from 3.5 to 7 mm and its unique design ensures excellent wall apposition. After the particles have been captured, the FiberNet filter is retrieved into the retrieval catheter under aspiration and removed from the patient.

The FiberNet EPS was evaluated in the EPIC (Evaluating the Use of the FiberNet EPS in Carotid Artery Stenting) multicenter trial, which demonstrated the lowest stroke rates of any filter currently available in the U.S. market. As part of the trial, 237 high-surgical-risk patients with a critical carotid artery stenosis received carotid artery stenting. Overall, the 30-day stroke rate was 2.1 percent. There were no unanticipated adverse device effects. Visible debris was observed in over ninety percent of the procedures.

“The FiberNet EPS has several attributes including ease of use, low profile and the ability to conform to an irregular surface in the vessel wall, that have contributed to the impressive results and safety profile we observed in the EPIC trial,” said Dr. Subbarao Myla, medical director of cardiovascular research and endovascular intervention at Hoag Memorial Hospital in California and national principle investigator for the trial. “The device achieved the lowest stroke rate of any filter currently available, making FiberNet a top choice for physicians, and represents the next generation in embolic protection.”

Invatec’s carotid portfolio consists of the Mo.Ma Proximal Protection Device and the Cristallo Ideale Carotid Stent System, both of which have received CE Marks. In the U.S., Invatec currently has a pivotal investigational device exemption clinical trial called ARMOUR underway to assess the safety and efficacy of the Mo.Ma Proximal Protection Device for use in carotid stenting with FDA approved carotid stents.

For more information:

Related Content

FDA clears Claret Medical Sentinel embolic protection device for TAVR
Feature | Heart Valve Technology| June 09, 2017
June 5, 2017 – The U.S.
Contego Medical Receives CE Mark for Vanguard IEP Peripheral Balloon Angioplasty System
News | Peripheral Artery Disease (PAD)| May 17, 2017
Contego Medical LLC announced recently that it has received CE Marking of its Vanguard IEP Peripheral Balloon...
PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device
News | Embolic Protection Devices| April 11, 2017
Through a new clinical trial, patients at Harrisburg, Pa.-based PinnacleHealth have access to an investigational device...
Cardiogard embolic protection system for surgical valve reaplacement

The CardioGard embolic protection system for surgical aortic valve replacement.

Feature | Embolic Protection Devices| March 22, 2017
March 22, 2017 — Two U.S.
InspireMD, CGuard embolic protection system, EPS, clinical data, internal carotid artery stenosis, ICA
News | Stents Carotid| November 18, 2016
November 18, 2016 — InspireMD Inc.
Sponsored Content | Videos | Heart Valve Technology| November 08, 2016
Studies have shown transcatheter aortic valve replacement (TAVR) has an increased risk of stroke and cerebral damage
TAVR, post-procedure, brain lesions, delirium, TCT 2016, Peter R. Stella
News | Heart Valve Technology| November 07, 2016
Keystone Heart Ltd. announced that data presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2016...
Sentinel, TAVR, TAVI, embloic protection
News | Heart Valve Technology| November 07, 2016
November 7, 2016 – A multicenter randomized trial evaluating the role of embolic protection using the Sentinel device
Keystone Heart, TriGuard Embolic Protection Device, real-world results, PCR London Valves Conference 2016
News | Embolic Protection Devices| September 29, 2016
Keystone Heart Ltd. recently announced the safety and efficacy of the TriGuard Cerebral Embolic Protection device...
Overlay Init